Stevanato Group S.p.A. (STVN)
USD 21.72
(-1.65%)
USD 21.72
(-1.65%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 329.39 Million EUR | 3275.15% |
| 2022 | -10.37 Million EUR | 93.78% |
| 2021 | -166.75 Million EUR | -167.4% |
| 2020 | 247.41 Million EUR | -14.77% |
| 2019 | 290.28 Million EUR | 19.68% |
| 2018 | 242.55 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 237.88 Million EUR | 26.57% |
| 2024 Q1 | 187.83 Million EUR | -42.98% |
| 2023 Q3 | 230.93 Million EUR | 81.05% |
| 2023 Q2 | 127.55 Million EUR | 85.46% |
| 2023 FY | 329.39 Million EUR | 3275.15% |
| 2023 Q1 | 68.77 Million EUR | 762.97% |
| 2023 Q4 | 329.39 Million EUR | 42.63% |
| 2022 Q3 | -23.73 Million EUR | 71.26% |
| 2022 Q2 | -82.59 Million EUR | 30.13% |
| 2022 FY | -10.37 Million EUR | 93.78% |
| 2022 Q1 | -118.2 Million EUR | 29.11% |
| 2022 Q4 | -10.37 Million EUR | 56.3% |
| 2021 Q1 | 275.22 Million EUR | 11.24% |
| 2021 FY | -166.75 Million EUR | -167.4% |
| 2021 Q3 | -139.12 Million EUR | -160.05% |
| 2021 Q2 | 231.65 Million EUR | -15.83% |
| 2021 Q4 | -166.75 Million EUR | -19.86% |
| 2020 Q4 | 247.41 Million EUR | 0.0% |
| 2020 FY | 247.41 Million EUR | -14.77% |
| 2020 Q1 | 126.27 Million EUR | 0.0% |
| 2019 FY | 290.28 Million EUR | 19.68% |
| 2018 FY | 242.55 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alcon Inc. | 4.04 Billion USD | 91.866% |
| AptarGroup, Inc. | 961.03 Million USD | 65.725% |
| Baxter International Inc. | 11.16 Billion USD | 97.05% |
| Becton, Dickinson and Company | 14.46 Billion USD | 97.723% |
| Bausch + Lomb Corporation | 4.23 Billion USD | 92.215% |
| Haemonetics Corporation | 695.08 Million USD | 52.611% |
| Envista Holdings Corp | 713.6 Million USD | 53.841% |
| ResMed Inc. | 635.57 Million USD | 48.174% |
| Teleflex Incorporated | 1.7 Billion USD | 80.664% |
| Warby Parker Inc. | -42.43 Million USD | 876.187% |
| West Pharmaceutical Services, Inc. | -544.9 Million USD | 160.45% |